Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05677048 · ClinicalTrials.gov registry record · NA
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
A NA study of Breast Cancer and Pancreatic Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 205
- Enrollment target
- 1
- Study location
NCT05677048: Active NA study of Breast Cancer and Pancreatic Cancer, sponsored by M.D. Anderson Cancer Center.
NCT05677048 is a NA study of Breast Cancer and Pancreatic Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 205 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05677048, a NA study of Breast Cancer and Pancreatic Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome. The two main factors in this study are the IGNITE-TX intervention (website and navigator) and the free genetic counseling and testing. The IGNITE-TX Intervention is an innovative multi-modal intervention, with two components: a) interactive web "IGNITE-TX Hub" and b) genetic family navigators.
Conditions Studied
Interventions
- BEHAVIORAL Free genetic testing and counseling group
- BEHAVIORAL IGNITE-TX Group
- BEHAVIORAL IGNITE-TX and free genetic testing and counseling group
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2023-04-14 |
| Est. Completion | 2027-10-31 |
| Phase | NA |
What the registry record for NCT05677048 still lists
NCT05677048 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Free genetic testing and counseling group is the first listed.
NCT05677048 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05677048 about?
NCT05677048 is a clinical study titled "Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention". This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome. The two main factors in this study are the IGNITE-TX intervention (website and n...
What is the current status of trial NCT05677048?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 205 participants. The study started on 2023-04-14. Estimated completion is 2027-10-31.
What conditions does trial NCT05677048 study?
This clinical trial studies the following conditions: Breast Cancer, Pancreatic Cancer, Endometrial Cancer, Colon Cancer, Gynecologic Cancer.
What interventions are being tested in trial NCT05677048?
The interventions under investigation include: Free genetic testing and counseling group (BEHAVIORAL), IGNITE-TX Group (BEHAVIORAL), IGNITE-TX and free genetic testing and counseling group (BEHAVIORAL).
Who is sponsoring clinical trial NCT05677048?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05677048 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05677048's enrollment target sits among peer trials
205 357th of 1224 higher than 867 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI